Find out more about our clinical trials: Read More

Transforming the Future of Immunotherapy


Founder, Chief Science Officer, Director

Theresa A. Deisher, Ph.D.

Theresa Deisher | LinkedIn
Doctoral degree in Molecular and Cellular Physiology from Stanford University School of Medicine. Holds more than 47 issued US/EU/Japan patents and 4 discoveries in clinical trials. Over 30 years of pharmaceutical leadership experience including Genentech, Repligen, ZymoGenetics, Immunex, and Amgen.


Jim Scully, CFO

Jim Scully | LinkedIn Jim has 30 years of pharmaceutical and healthcare experience, including senior leadership roles in finance, operations, business development and general management.  His subject-matter knowledge spans commercial, clinical development and manufacturing operations.  Jim received an MBA in Finance from the University of Chicago and a BS from the University of Pennsylvania, Wharton School of Business.  

Chief Medical Officer - Compassionate Use Program

Edward Loniewski, D.O.

Edward Loniewski | LinkedIn
Michigan State University, College of Osteopathic Medicine. University of Chicago Fellowship Arthritis & Adult Reconstruction. Founder Cellular Healing.

VP of Investor Relations

Terry Kopp

Terrence (Terry) Kopp had a successful 27-year history in marketing and sales with a major programming network in cable TV and has served in investor relations leadership for AVM Biotechnology since 2014, including leading series B, C, and D raises.

Director of Lab Research

Peter Jarzyna, Ph.D.

Peter Jarzyna | LinkedIn
Dr. Jarzyna received his Ph.D. in Pharmacy (tumor biology/imaging) from the University of Regensburg in Germany. While doing postdoctoral work at Mount Sinai Hospital in New York City, NY and later at Harvard Medical School in Boston, MA, he gained international experience in the field of preclinical cancer/imaging research and has successfully led many projects.

Advisory Board

Scientific & Clinical Advisor

William Matsui, M.D.

William Matsui | LinkedIn
Deputy Director Livestrong Cancer Institutes, Professor Department of Oncology, Dell Medical School, received his AB in Biochemistry from Harvard and M.D. from the University of California SanFrancisco. Dr. Matsui has carried out research throughout his career making several key discoveries in clinical oncology.

Scientific & Clinical Advisor

Frank Buttgereit, M.D.

Frank Buttgereit | LinkedIn
Senior Consultant and Deputy Director, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin. Professor of Rheumatology, Charité Universitätsmedizin Berlin. 

Scientific & Clinical Advisor

Gordon Roble, D.V.M.

Gordon Roble | LinkedIn
Dr. Roble is Director of Comparative Medicine at Fred Hutchinson Cancer Research Center. He received his MBA from NYU, his Doctor of Veterinary Medicine from Tufts University, and BA in Biology from Swarthmore College.

Scientific & Clinical Advisor

Gianpietro Dotti, M.D.

Director of the Immunotherapy Program at the University of North Carolina Lineberger Comprehensive Cancer Center and professor in the Department of Microbiology and Immunology at University of North Carolina at Chapel Hill. He received his medical degree from the University of Milan in Italy, with further training in hematology from the University of Parma and a post-doctoral fellowship from Baylor College of Medicine in Houston, Texas.

AVM Biotechnology’s Clinical Trial for Non-Hodgkin’s Lymphoma/Leukemia is Actively Enrolling